CA2886991A1 - Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs - Google Patents
Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs Download PDFInfo
- Publication number
- CA2886991A1 CA2886991A1 CA2886991A CA2886991A CA2886991A1 CA 2886991 A1 CA2886991 A1 CA 2886991A1 CA 2886991 A CA2886991 A CA 2886991A CA 2886991 A CA2886991 A CA 2886991A CA 2886991 A1 CA2886991 A1 CA 2886991A1
- Authority
- CA
- Canada
- Prior art keywords
- ibs
- bacterial antigen
- level
- antigen antibody
- markers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000003630 histaminocyte Anatomy 0.000 title claims description 153
- 244000005700 microbiome Species 0.000 title description 10
- 208000002551 irritable bowel syndrome Diseases 0.000 claims abstract description 371
- 239000000523 sample Substances 0.000 claims abstract description 242
- 238000000034 method Methods 0.000 claims abstract description 165
- 238000003745 diagnosis Methods 0.000 claims abstract description 56
- 108091007433 antigens Proteins 0.000 claims description 414
- 102000036639 antigens Human genes 0.000 claims description 414
- 239000000427 antigen Substances 0.000 claims description 409
- 230000001580 bacterial effect Effects 0.000 claims description 351
- 239000003550 marker Substances 0.000 claims description 172
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 110
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 102
- 239000012634 fragment Substances 0.000 claims description 86
- 239000002771 cell marker Substances 0.000 claims description 80
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 60
- 229960001340 histamine Drugs 0.000 claims description 56
- 241000588724 Escherichia coli Species 0.000 claims description 54
- 229960002986 dinoprostone Drugs 0.000 claims description 54
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 53
- 229960000890 hydrocortisone Drugs 0.000 claims description 51
- 241000589875 Campylobacter jejuni Species 0.000 claims description 50
- 230000000890 antigenic effect Effects 0.000 claims description 44
- 108010079246 OMPA outer membrane proteins Proteins 0.000 claims description 40
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 38
- 238000007619 statistical method Methods 0.000 claims description 32
- 239000012472 biological sample Substances 0.000 claims description 30
- 238000007477 logistic regression Methods 0.000 claims description 28
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 26
- 208000015181 infectious disease Diseases 0.000 claims description 26
- 239000002438 stress hormone Substances 0.000 claims description 22
- 238000001514 detection method Methods 0.000 claims description 20
- 241000607762 Shigella flexneri Species 0.000 claims description 19
- 101000851240 Homo sapiens Elongation factor Tu, mitochondrial Proteins 0.000 claims description 18
- 102100033238 Elongation factor Tu, mitochondrial Human genes 0.000 claims description 17
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 16
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 16
- 206010010774 Constipation Diseases 0.000 claims description 16
- 229940076279 serotonin Drugs 0.000 claims description 16
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims description 15
- 206010012735 Diarrhoea Diseases 0.000 claims description 15
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 15
- 229960000258 corticotropin Drugs 0.000 claims description 15
- 241001468157 Lactobacillus johnsonii Species 0.000 claims description 11
- 241000605861 Prevotella Species 0.000 claims description 10
- 241000193468 Clostridium perfringens Species 0.000 claims description 4
- 241001646719 Escherichia coli O157:H7 Species 0.000 claims description 3
- 241000421809 Brisaster fragilis Species 0.000 claims 1
- 241000495778 Escherichia faecalis Species 0.000 claims 1
- 238000012896 Statistical algorithm Methods 0.000 abstract description 14
- 238000011282 treatment Methods 0.000 abstract description 8
- 239000013068 control sample Substances 0.000 abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 136
- 150000001413 amino acids Chemical group 0.000 description 111
- 102000004196 processed proteins & peptides Human genes 0.000 description 98
- 229920001184 polypeptide Polymers 0.000 description 95
- 108090000623 proteins and genes Proteins 0.000 description 78
- 102000004169 proteins and genes Human genes 0.000 description 78
- 235000018102 proteins Nutrition 0.000 description 77
- 238000003556 assay Methods 0.000 description 57
- 241000894006 Bacteria Species 0.000 description 54
- 108010040721 Flagellin Proteins 0.000 description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 45
- 210000002966 serum Anatomy 0.000 description 42
- 208000024891 symptom Diseases 0.000 description 35
- 201000010099 disease Diseases 0.000 description 33
- 239000007790 solid phase Substances 0.000 description 27
- 241000588722 Escherichia Species 0.000 description 26
- 241000736262 Microbiota Species 0.000 description 26
- 239000000243 solution Substances 0.000 description 26
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 25
- 238000010647 peptide synthesis reaction Methods 0.000 description 25
- 108020004707 nucleic acids Proteins 0.000 description 24
- 102000039446 nucleic acids Human genes 0.000 description 24
- 150000007523 nucleic acids Chemical class 0.000 description 24
- 238000000746 purification Methods 0.000 description 24
- 238000003259 recombinant expression Methods 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 102000004190 Enzymes Human genes 0.000 description 19
- 108090000790 Enzymes Proteins 0.000 description 19
- 229940088598 enzyme Drugs 0.000 description 19
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 238000004422 calculation algorithm Methods 0.000 description 18
- 229940015062 campylobacter jejuni Drugs 0.000 description 17
- 230000002496 gastric effect Effects 0.000 description 17
- 239000000090 biomarker Substances 0.000 description 16
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 15
- 239000000758 substrate Substances 0.000 description 14
- -1 BONE Chemical compound 0.000 description 13
- 101800000414 Corticotropin Proteins 0.000 description 13
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 13
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 13
- 238000012544 monitoring process Methods 0.000 description 13
- 201000003379 Townes-Brocks syndrome Diseases 0.000 description 12
- 241000606124 Bacteroides fragilis Species 0.000 description 11
- 241000194032 Enterococcus faecalis Species 0.000 description 11
- 241000208202 Linaceae Species 0.000 description 11
- 235000004431 Linum usitatissimum Nutrition 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 10
- 238000007637 random forest analysis Methods 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 241000186779 Listeria monocytogenes Species 0.000 description 9
- 238000001574 biopsy Methods 0.000 description 9
- 208000011231 Crohn disease Diseases 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 239000013024 dilution buffer Substances 0.000 description 7
- 238000003018 immunoassay Methods 0.000 description 7
- 208000028774 intestinal disease Diseases 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 238000004020 luminiscence type Methods 0.000 description 7
- 238000010801 machine learning Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 208000015943 Coeliac disease Diseases 0.000 description 6
- 241000607768 Shigella Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 244000005709 gut microbiome Species 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 210000003296 saliva Anatomy 0.000 description 6
- 102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 description 5
- 108010074051 C-Reactive Protein Proteins 0.000 description 5
- 102100032752 C-reactive protein Human genes 0.000 description 5
- 108010078791 Carrier Proteins Proteins 0.000 description 5
- 241001112696 Clostridia Species 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 241000611831 Prevotella sp. Species 0.000 description 5
- 102000001400 Tryptase Human genes 0.000 description 5
- 108060005989 Tryptase Proteins 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- 230000007149 gut brain axis pathway Effects 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000002864 sequence alignment Methods 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 101710094518 4-aminobutyrate aminotransferase Proteins 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 241000589876 Campylobacter Species 0.000 description 4
- 241000193403 Clostridium Species 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 241001112693 Lachnospiraceae Species 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000009266 disease activity Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000002055 immunohistochemical effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 238000012417 linear regression Methods 0.000 description 4
- 208000008275 microscopic colitis Diseases 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 4
- 229960003040 rifaximin Drugs 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000000405 serological effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 206010000159 Abnormal loss of weight Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 241001646716 Escherichia coli K-12 Species 0.000 description 3
- 101000821449 Homo sapiens Secreted and transmembrane protein 1 Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 241000186781 Listeria Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 102100021853 Secreted and transmembrane protein 1 Human genes 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 238000013528 artificial neural network Methods 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 210000003495 flagella Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 3
- 210000005095 gastrointestinal system Anatomy 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000003938 response to stress Effects 0.000 description 3
- 238000013179 statistical model Methods 0.000 description 3
- 239000012089 stop solution Substances 0.000 description 3
- 238000012706 support-vector machine Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 101710115046 4-aminobutyrate aminotransferase, mitochondrial Proteins 0.000 description 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- 108091005471 CRHR1 Proteins 0.000 description 2
- 108091005470 CRHR2 Proteins 0.000 description 2
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241001464956 Collinsella Species 0.000 description 2
- 102100038018 Corticotropin-releasing factor receptor 1 Human genes 0.000 description 2
- 102100038019 Corticotropin-releasing factor receptor 2 Human genes 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 101710111023 GTPase Obg/CgtA Proteins 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 101710164702 Major outer membrane protein Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
- 208000037062 Polyps Diseases 0.000 description 2
- 101000992168 Porphyromonas gingivalis (strain ATCC BAA-308 / W83) Outer membrane protein 40 Proteins 0.000 description 2
- 101710194807 Protective antigen Proteins 0.000 description 2
- 241000192142 Proteobacteria Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010038063 Rectal haemorrhage Diseases 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 2
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 238000012084 abdominal surgery Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 210000005006 adaptive immune system Anatomy 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000003431 anti-prostaglandin Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 241000395146 bacterium A4 Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003150 biochemical marker Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 238000002052 colonoscopy Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 2
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 108010028610 formyl-coenzyme A transferase Proteins 0.000 description 2
- 230000005934 immune activation Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 208000008585 mastocytosis Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 238000007392 microtiter assay Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 210000004760 visceral afferent Anatomy 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108030001082 (S)-3-amino-2-methylpropionate transaminases Proteins 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- 108010060511 4-Aminobutyrate Transaminase Proteins 0.000 description 1
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241001156739 Actinobacteria <phylum> Species 0.000 description 1
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 241001135756 Alphaproteobacteria Species 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 241001135755 Betaproteobacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000186560 Blautia coccoides Species 0.000 description 1
- 101100447653 Caenorhabditis elegans phg-1 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102100032219 Cathepsin D Human genes 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102100026096 Claudin-8 Human genes 0.000 description 1
- 241001443882 Coprobacillus Species 0.000 description 1
- 241001464948 Coprococcus Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 241001135761 Deltaproteobacteria Species 0.000 description 1
- 244000182625 Dictamnus albus Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241001143779 Dorea Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241001148568 Epsilonproteobacteria Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 206010061958 Food Intolerance Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 206010017367 Frequent bowel movements Diseases 0.000 description 1
- 241001453172 Fusobacteria Species 0.000 description 1
- 241000192128 Gammaproteobacteria Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 102000006485 Glutamyl Aminopeptidase Human genes 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 102100025255 Haptoglobin Human genes 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100449532 Homo sapiens CXCL1 gene Proteins 0.000 description 1
- 101000869010 Homo sapiens Cathepsin D Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 description 1
- 101000830742 Homo sapiens Tryptophan 5-hydroxylase 1 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000005712 Keratin-8 Human genes 0.000 description 1
- 108010070511 Keratin-8 Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000928987 Lachnospiraceae bacterium A4 Species 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
- 238000012897 Levenberg–Marquardt algorithm Methods 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 102400001103 Neurotensin Human genes 0.000 description 1
- 101800001814 Neurotensin Proteins 0.000 description 1
- 108700002045 Nod2 Signaling Adaptor Proteins 0.000 description 1
- 101150083031 Nod2 gene Proteins 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 108700028353 OmpC Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 108010049977 Peptide Elongation Factor Tu Proteins 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 241000480383 Prevotella sp. oral taxon 472 str. F0295 Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710201515 Putative aminopeptidase Proteins 0.000 description 1
- 101710156978 Ras-like protein Proteins 0.000 description 1
- 241000691806 Rhinobatos productus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000192031 Ruminococcus Species 0.000 description 1
- 102000013674 S-100 Human genes 0.000 description 1
- 108700021018 S100 Proteins 0.000 description 1
- 101100348089 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) BUR6 gene Proteins 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 101100173866 Shigella flexneri fliC gene Proteins 0.000 description 1
- 101000579490 Solanum lycopersicum Suberization-associated anionic peroxidase 1 Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- 101710126110 Surface protein F Proteins 0.000 description 1
- 102000003141 Tachykinin Human genes 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102000008234 Toll-like receptor 5 Human genes 0.000 description 1
- 108010060812 Toll-like receptor 5 Proteins 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100024971 Tryptophan 5-hydroxylase 1 Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 description 1
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241001148134 Veillonella Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- QWXOJIDBSHLIFI-UHFFFAOYSA-N [3-(1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC2CC(Cl)(C4)C3)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 QWXOJIDBSHLIFI-UHFFFAOYSA-N 0.000 description 1
- 241000985257 [Clostridium] cocleatum Species 0.000 description 1
- 241001531188 [Eubacterium] rectale Species 0.000 description 1
- 241001464870 [Ruminococcus] torques Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 230000000356 anti-lactoferrin effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000009388 chemical precipitation Methods 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 108090000239 claudin 8 Proteins 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 210000002049 efferent pathway Anatomy 0.000 description 1
- 229940096118 ella Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 108010003342 flaB flagellin Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000010243 gut motility Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004179 indigotine Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 241000514897 mixed subtypes Species 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 108060008037 tachykinin Proteins 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 108010027843 zonulin Proteins 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261710574P | 2012-10-05 | 2012-10-05 | |
| US61/710,574 | 2012-10-05 | ||
| US201361871853P | 2013-08-29 | 2013-08-29 | |
| US61/871,853 | 2013-08-29 | ||
| PCT/IB2013/059045 WO2014053996A2 (en) | 2012-10-05 | 2013-10-01 | Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2886991A1 true CA2886991A1 (en) | 2014-04-10 |
Family
ID=49447585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2886991A Abandoned CA2886991A1 (en) | 2012-10-05 | 2013-10-01 | Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10184940B2 (enExample) |
| EP (1) | EP2904395B1 (enExample) |
| JP (1) | JP6329553B2 (enExample) |
| CN (1) | CN104884959B (enExample) |
| AU (1) | AU2013326133B2 (enExample) |
| CA (1) | CA2886991A1 (enExample) |
| MX (1) | MX360479B (enExample) |
| SG (2) | SG11201502641YA (enExample) |
| WO (1) | WO2014053996A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0720250D0 (en) * | 2007-10-17 | 2007-11-28 | Univ Edinburgh | Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof |
| US20160096819A1 (en) * | 2013-05-17 | 2016-04-07 | Basf Se | Process for preparing n-substituted 1h-pyrazole-5-carboxylic acid compounds and derivatives thereof |
| RU2015155552A (ru) | 2013-05-24 | 2017-06-27 | Нестек С.А. | Путеспецифические способы прогнозирования диагноза синдрома раздраженного кишечника |
| WO2017079653A2 (en) | 2015-11-06 | 2017-05-11 | Vetica Labs, Inc. | Methods of detecting inflammatory markers and treating inflammatory conditions in companion animals |
| EP3421616A1 (en) * | 2017-06-29 | 2019-01-02 | Tata Consultancy Services Limited | Method and system for monitoring the gut health of an individual |
| CN111432825A (zh) * | 2017-10-03 | 2020-07-17 | 赛里斯治疗公司 | 色胺代谢的操纵 |
| JP6533930B1 (ja) * | 2018-08-23 | 2019-06-26 | 一般社団法人日本農業フロンティア開発機構 | 疾病評価指標算出方法、装置、システム、及び、プログラム、並びに、疾病評価指標を算出するためのモデル作成方法。 |
| US11884958B2 (en) | 2019-04-30 | 2024-01-30 | Mayo Foundation For Medical Education And Research | Assessing and treating functional gastrointestinal disorders |
| WO2025071560A1 (en) * | 2023-09-28 | 2025-04-03 | Rutgers, The State University Of New Jersey | Methods of diagnosing b cell malignancies, detecting b cell malignancy relapse, and treating thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003298703A1 (en) * | 2002-11-22 | 2004-06-18 | Emory University | Diagnostic tests and methods for diagnosing inflammatory bowel disease |
| US20060154276A1 (en) * | 2004-05-13 | 2006-07-13 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
| US7943328B1 (en) * | 2006-03-03 | 2011-05-17 | Prometheus Laboratories Inc. | Method and system for assisting in diagnosing irritable bowel syndrome |
| US20080085524A1 (en) | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| US20100094560A1 (en) * | 2006-08-15 | 2010-04-15 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| WO2011027971A2 (ko) * | 2009-09-01 | 2011-03-10 | 주식회사이언메딕스 | 장내 공생 세균유래 세포밖 소포체, 및 이를 이용한 질병모델, 백신, 후보 약물 탐색 방법, 및 진단 방법 |
| EP2494074A4 (en) * | 2009-10-30 | 2013-06-12 | Nestec Sa | METHOD FOR DIAGNOSING IRRITATION SYNDROME |
-
2013
- 2013-10-01 JP JP2015535149A patent/JP6329553B2/ja not_active Expired - Fee Related
- 2013-10-01 CN CN201380063446.2A patent/CN104884959B/zh not_active Expired - Fee Related
- 2013-10-01 AU AU2013326133A patent/AU2013326133B2/en not_active Expired - Fee Related
- 2013-10-01 MX MX2015004271A patent/MX360479B/es active IP Right Grant
- 2013-10-01 WO PCT/IB2013/059045 patent/WO2014053996A2/en not_active Ceased
- 2013-10-01 EP EP13779635.5A patent/EP2904395B1/en not_active Not-in-force
- 2013-10-01 SG SG11201502641YA patent/SG11201502641YA/en unknown
- 2013-10-01 CA CA2886991A patent/CA2886991A1/en not_active Abandoned
- 2013-10-01 SG SG10201702773QA patent/SG10201702773QA/en unknown
-
2015
- 2015-03-30 US US14/673,660 patent/US10184940B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX360479B (es) | 2018-11-05 |
| EP2904395A2 (en) | 2015-08-12 |
| SG10201702773QA (en) | 2017-06-29 |
| US10184940B2 (en) | 2019-01-22 |
| EP2904395B1 (en) | 2018-09-05 |
| WO2014053996A3 (en) | 2014-05-30 |
| SG11201502641YA (en) | 2015-05-28 |
| CN104884959A (zh) | 2015-09-02 |
| AU2013326133B2 (en) | 2019-07-04 |
| JP6329553B2 (ja) | 2018-05-23 |
| JP2015533213A (ja) | 2015-11-19 |
| CN104884959B (zh) | 2017-12-01 |
| US20150346200A1 (en) | 2015-12-03 |
| MX2015004271A (es) | 2015-08-14 |
| HK1213050A1 (en) | 2016-06-24 |
| WO2014053996A2 (en) | 2014-04-10 |
| AU2013326133A1 (en) | 2015-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10184940B2 (en) | Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for IBS | |
| US10338083B2 (en) | Pathway specific markers for diagnosing irritable bowel syndrome | |
| US20120276060A1 (en) | Fecal lactoferrin as a biomarker for determining disease severity and for treating infection in patients with clostridium difficile disease | |
| US20130137123A1 (en) | Use of hmgb1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof | |
| ES3028294T3 (en) | Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease | |
| JP2020106537A (ja) | 心臓障害のマーカーとしての１３＋／１７＋ｂｉｎ１発現 | |
| JP6193976B2 (ja) | バイオマーカーとしてのクロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）・デヒドロゲナーゼおよび毒素 | |
| HK1213050B (en) | Antibodies to microbiome as diagnostic markers for ibs | |
| RU2572717C1 (ru) | Способ иммунодиагностики заболеваний, вызванных helicobacter pylori-инфекцией | |
| JP7740807B2 (ja) | 敗血症原因細菌の免疫学的分析方法及び該方法に用いるモノクローナル抗体 | |
| WO2009135257A1 (en) | Methods of diagnosis of inflammatory bowel disease | |
| Bayoumi et al. | Antivinculin antibodies as a marker of irritable bowel syndrome–diarrhea in Egyptian patients | |
| JP2024522606A (ja) | 機能性消化管障害のための診断マーカー | |
| HK1223416B (en) | Method for diagnosing irritable bowel syndrome | |
| NZ701004B2 (en) | Clostridium difficile dehydrogenase and toxin as a biomarker |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20161004 |
|
| FZDE | Discontinued |
Effective date: 20201207 |